Drug Profile
Research programme: heart disease therapies - Incyte
Alternative Names: MX 6120Latest Information Update: 05 Oct 2006
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class
- Mechanism of Action Endothelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 05 Oct 2006 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 30 Apr 2003 Incyte Genomics is now called Incyte Corporation
- 03 Mar 2003 Maxia Pharmaceuticals has been acquired by Incyte Genomics